Search PubMed⌕ Search

Biomedical subjects

E Scherer

Publications and source records attributed to E Scherer.

At least 109 records · Page 6Linked to original sources
PubMed1979

[Combined chemotherapy and radiotherapy of localized and metastasizing Ewing's sarcoma (author's transl)].

Between 1973 and 1978 combined radiotherapy and chemotherapy were given to 22 patients with histologically proven Ewing's sarcoma. The combined chemotherapy consisted of cyclophosphamide, vincristin, adriamycin, as well as dacarbazine in some cases. The neoplasm was a localized one at the beginning of treatment in 14 of the 22. These patients received high-voltage radiotherapy to the primary focus at a focal dose between 42 and 55 Gray (4200-5500 rad), followed by chemotherapy. After 6--8 treatment cycles, adriamycin was replaced by methotrexate. Nine of the 14 patients survived without recurrence for 12 to over 59 months. Eight patients had extensive metastases at the beginning of treatment: they at first received only chemotherapy, followed by radiotherapy or operation, as indicated. Full clinical remission was achieved in five of them: in three this remission has now lasted for more than 18, 40 and 44 months, respectively. These results indicate that (1) additional chemotherapy improves the prognosis of localized Ewing's sarcoma, and (2) even in far-progressed cases the combination of chemotherapy and radiotherapy can achieve lasting remission, which may in fact be a true cure.

Adolescent↗
PubMed1979

[Local recurrences in keratoid squamous cell carcinomas of the oral cavity: incidence, causes and therapy after a curative primary treatment (author's transl)].

The frequency of local recurrences in keratoid squamous cell carcinomas of the oral cavity is analyzed in view of the following criteria: Irradiation technique, volume of the primary tumor, irradiation parameters considering the factor of dose and time. The values of the dose, measured by ret, were calculated using the Ellis-formula modified by Gabriel-Jürgens et al. A focal dose of 1,700 ret is recommended for Stage T1 carcinomas of the tongue, a dose of 1,900 ret for the stages T2 and T3. The importance of the concept of nominal standard dose is emphasized with regard to its clinical application. Surgery seems to be superior to the renewal of radiation therapy in the treatment of recurrences.

Adult↗
PubMed1979

[Problems in radiation therapy for carcinoma of the rectum (author's transl)].

The role of radiation therapy within the total treatment for carcinoma of the rectum is reported in this paper. Early treatment with radiological contact methods as well as systemic post operative irradiation of advanced tumor stages are interpreted in detail, and attention is drawn to the importance of pre-operative irradiation meanwhile being tested at many places. Therapy of recurrences and of inoperable tumor stages, including chemotherapy, is explained on the basis of own experiences and of reviewing the data of the literature.

Humans↗
PubMed1979

[Preliminary results of the pilot phase of neutron treatment in Essen (author's transl)].

In agreement with the EORTC Charged Particle Therapy Project Group, a pilot phase of neutron treatment was performed on 59 patients in 1978. All patients suffered from far-advanced tumours. Sixteen were treated with neutrons exclusively, while all the others had recurrences after chemotherapy, surgery, or combined surgery and photon- or electron therapy. 29 of them received reduced doses (10 to 14 Gy), thirty patients got a full neutron course of 16 Gy (Total Effective Dose). The observation time varied from 2 to 11 months. Serious side effects occurred in 11 cases. A complete tumour regression was achieved in 35 patients, and a partial regression in 17. Recurrences developed in 5 cases, no tumour regression was seen in 2 cases. These preliminary results encouraged us to start a randomized trial of head and neck tumours according to the protocols of the EORTC Charged Particle Therapy Project Group.

Humans↗
PubMed1978

[Low-dose x-ray treatment of 44 haemangiomas of the lid (author's transl)].

An extent knowledge of different haemangioma forms is the prerequisite of any treatment of haemangioma. Only the blastomatous haemangioma, because of its histological substrate, has a marked sensitivity to x-radiation. The tendency towards spontaneous regression among haemangiomas is an important factor which must be taken into consideration in any treatment plan. The blastomatous haemangiomas are most radiation-sensitive during the growth phase. For this reason such treatment should be undertaken in the first two years of life and under quite specific indications. The results of low-dose radiotherapy was assessed five years after the end of treatment on 157 patients with haemangiomas (of these, 44 were of the lid). Very good to satisfactory results had been achieved in 95.5% of blastomatous haemangiomas. Radiotherapy was only little effective in juveniles and adults. These results indicate that radiotherapy is the treatment of choice for blastomatous haemangiomas.

Age Factors↗
PubMed1978

[Endolymphatic radionuclide therapy of the malignant melanoma (author's transl)].

In the radiological hospital of Essen, 139 patients with malignant melanomas on the extremities have been submitted to an endolymphatic radionuclide therapy between May 29, 1970 and January 1, 1976. The survival rates of the different tumor stages are indicated and the changes of the survival curves since the last evaluation of August 31, 1973 are discussed. If the endolymphatic radionuclide therapy is applied, there is no risk of important side effects or complications. If an adequate surgical therapy has been effected prior to the radiotherapy, we consider the endolymphatic radionuclide therapy to be indicated above all in case of a malignant melanoma of the clinical stage I or II when the primary tumor is situated in the lower extremity.

Female↗
PubMed1978

[Radiotherapy of blastomatous hemangiomas - under special consideration of 44 eyelid hemangiomas (author's transl)].

The propriety of blastomatous hemangiomas to show spontaneous regression is underlined. Under certain indications, above all in case of eyelid hemangiomas, a radiotherapy is indicated. The moment of manifestation lies within the first three months of life, and the female sex is affected two times more frequently. The head represents the predilection spot within the distribution scheme of hemangiomas. 44 patients with eyelid hemangiomas who had been treated between 1968 and 1972 by the described irradiation method had check-up appointments five years later. The therapeutical results were evaluated according to certain criteria. 95,5% of the blastomatous hemangiomas showed a very good or satisfactory regression. Only 4,5% did not present any satisfactory success. In an advanced age of the patients, the hemangiomas do not always respond favourably to radiotherapy. In case of a strictly executed indication and a faultless irradiation technique, irradiation damages can be avoided. Our results show that, with regard to the spontaneous regression of blastomatous hemangiomas, total doses of 1000 to 1500 rd are sufficient. Finally the authors cite the standpoints of radiotherapy concerning the treatment of blastomatous hemangiomas and give recommendations for dosage principles.

Age Factors↗